Provectus Biopharmaceuticals, INC Form 4 insider transactions

Edward Pershing, CEO of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock, according to a recent SEC Form 4 filing.

CEO Edward Pershing reports the conversion of a convertible promissory note into Series D-1 Convertible Preferred Stock and subsequent conversion into common stock.

Provectus Biopharmaceuticals CEO, Edward Pershing, acquired convertible promissory notes and preferred stock, potentially increasing his stake in the company.

CEO Edward Pershing reports the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Provectus Biopharmaceuticals CEO, Edward Pershing, acquired convertible promissory notes and preferred stock, potentially increasing his stake in the company.

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on December 28, 2024.

Director Webster Bailey acquired 775,082 stock options in Provectus Biopharmaceuticals on December 2, 2024.

Director John Lacey III acquired 775,082 stock options in Provectus Biopharmaceuticals on December 2, 2024.

Eric Wachter, CTO of Provectus Biopharmaceuticals, acquired 2,138,548 stock options on December 2, 2024, which vest in three equal annual installments.

Provectus Biopharmaceuticals' CFO, Heather Raines, was granted 4,197,890 stock options on December 2, 2024.

Dominic Rodrigues, President of Provectus Biopharmaceuticals, acquired 16.1 million stock options on December 2, 2024, which vest in three equal annual installments.

Provectus Biopharmaceuticals CEO, Edward Pershing, was granted 25.4 million stock options on December 2, 2024, which vest in three equal annual installments.

Provectus Biopharmaceuticals CEO, Edward Pershing, converted a promissory note into preferred stock, increasing his holdings in the company.

Provectus Biopharmaceuticals CEO, Edward Pershing, acquired 80,365 shares of Series D-1 Convertible Preferred Stock in a private transaction.

CEO Edward Pershing reports acquisition of convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.

Edward Pershing, CEO of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note that can be converted into Series D-1 Convertible Preferred Stock.

Director John Lacey III reports acquisition of Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.

Director Webster Bailey reports acquisition of Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.

Dominic Rodrigues, President of Provectus Biopharmaceuticals, reports acquisition of Series D-1 Convertible Preferred Stock convertible into 1,962,500 shares of common stock.

CEO Edward Pershing reports acquisition of Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.

CEO Edward Pershing acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals' 2024 Financing.

CEO Edward Pershing acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock as part of the Issuer's 2024 Financing.

CEO Edward Pershing acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals' 2024 Financing.

Director Jeffrey Allen Morris reports acquisition of Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.

CEO Edward Pershing reports acquisition of an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals' 2024 Financing.

CEO Edward Pershing reports the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Dominic Rodrigues, President of Provectus Biopharmaceuticals, converted Series D Convertible Preferred Stock into Series D-1 Convertible Preferred Stock on June 25, 2024.

CEO Edward Pershing reports the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

CEO Edward Pershing reports acquisition of convertible promissory note and preferred stock in Provectus Biopharmaceuticals.

CEO Edward Pershing acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock, potentially convertible into common stock, as part of the company's 2022 Financing.